Oncocyte Corporation (OCX) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. My name is Kayla and I will be your conference operator today. At this time, I'd like to welcome everyone to the OncoSite third quarter 2024 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you'd like to withdraw your question, again, press the star and 1. I would now like to turn the call over to Julie Silber, Senior Managing Director of PCG Advisory. You may begin. Thank you, Kayla. And thank you, everyone, for joining us for today's conference call to discuss OncoSite's third quarter 2024 financial results and recent operating highlights. If you have not seen today's shareholder letter, please visit Oncocyte's investor relations page at investors.oncocyte.com to read it. Today's prepared remarks build upon the information that was already shared in this robust letter. On today's call is Oncocyte's President and CEO, Josh Riggs, Chief Science Officer, Eke Schutz, and CFO, Andrea James. before turning the call over to josh i'd like to go over our safe harbor the company will make projections and forward-looking statements regarding future events any statements that are not historical are forward-looking statements these statements are made pursuant to and within the meaning of the safe harbor provision of the private securities litigation reform act of 1995. we encourage you to to review the company's SEC filings, including the company's most recent form 10Q, which identifies the risks and uncertainties that may cause future actual results or events to differ materially from those expressed or implied...